冀磊, 李占强, 芦殿香. HIF-2α在肺动脉高压中的研究进展J. 药学学报, 2022,57(2): 277-286. doi: 10.16438/j.0513-4870.2021-0632
引用本文: 冀磊, 李占强, 芦殿香. HIF-2α在肺动脉高压中的研究进展J. 药学学报, 2022,57(2): 277-286. doi: 10.16438/j.0513-4870.2021-0632
JI Lei, LI Zhan-qiang, LU Dian-xiang. Recent advances of HIF-2α in pulmonary hypertensionJ. Acta Pharmaceutica Sinica, 2022,57(2): 277-286. doi: 10.16438/j.0513-4870.2021-0632
Citation: JI Lei, LI Zhan-qiang, LU Dian-xiang. Recent advances of HIF-2α in pulmonary hypertensionJ. Acta Pharmaceutica Sinica, 2022,57(2): 277-286. doi: 10.16438/j.0513-4870.2021-0632

HIF-2α在肺动脉高压中的研究进展

Recent advances of HIF-2α in pulmonary hypertension

  • 摘要: 肺动脉高压(pulmonary hypertension,PH)是一种以肺血管阻力进行性增加、闭塞性血管重构为特征的疾病。低氧诱导因子-2α(hypoxia inducible factor-2 alpha,HIF-2α)是参与肺血管细胞异常增殖和肺血管重构过程的关键因子之一。本文主要从细胞水平、整体水平综述HIF-2α在PH发生中的作用及其机制,并对目前以HIF-2α为靶点治疗肺动脉高压的候选方案进行介绍,以期为PH发病机制的研究及有效治疗方法的筛选提供参考。

     

    Abstract: Pulmonary hypertension (PH) is a kind of disease characterized by progressive increase of pulmonary vascular resistance and occlusive vascular remodeling. Hypoxic inductive factor-2α (HIF-2α) plays an important role in the abnormal proliferation of pulmonary vascular cells and pulmonary vascular remodeling. This review focuses on the role of HIF-2α in pulmonary hypertension at the cellular and the global level, and candidates targeting HIF-2α for the treatment of pulmonary hypertension, in order to better understand the pathogenesis of PH and find effective treatments.

     

/

返回文章
返回